Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Potent antiplatelet agents like ticagrelor may be a reasonable choice for treating stent thrombosis even in patients with high bleeding risk from recent severe trauma.
Percutaneous transluminal coronary angioplasty with stent implantation is a basic life-saving treatment of stenotic lesions causing acute coronary syndromes. Stent thrombosis is one of the most serious complications of coronary angioplasty, strongly associated with recurrent myocardial infarction and high mortality. Many factors were identified as increasing the incidence of stent thrombosis including bleeding and inflammation. I am presenting a case of a 54-year-old man after extensive crushing injury of the lower limb with simultaneous stent thrombosis in two recently implanted stents. As a preventive measure for stent thrombosis novel potent antiplatelet agents may be a reasonable choice even for patients with high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Michał Kasprzak (2021) conducted a case report in Subacute stent thrombosis (n=1). Abciximab, ticagrelor, and balloon angioplasty was evaluated on Clinical outcome (survival and resolution of stent thrombosis).
Synapse has enriched 10 related papers. Consider them for comparative context: